{"entity":{"id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","aka":[],"tldr":"A phase 3 trial testing Pelabresib, now recruiting.","summary":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib is a phase 3 interventional study registered as NCT06401356, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib. Planned enrolment is 50 participants (estimated). The study started in 2024-08-13 and primary completion is expected in 2027-06-02. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06401356","url":"https://clinicaltrials.gov/study/NCT06401356"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["pelabresib"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06401356","phase":"3","setting":"An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib","sponsor":"Novartis Pharmaceuticals","started":"2024-08-13","startedType":"actual","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06401356/","neighbours":{"drug":[{"id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}